Founded on the basis that cancer treatments need to be more targeted to actually treat the cancer and not do significant harm to the patient, Seattle Genetics, led by Clay Siegall is succeeding in their battle against cancer. Clay knows first hand the devastating effects that cancer and traditional treatments can cause. Mr. Siegall saw a loved one go through a rigorous bout of cancer, almost passing away from the side effects of chemotherapy and became determined to put an end to patients having no options to traditional treatments.
Founded in 1998, Seattle Genetics has been the beneficiary of all of Clays hard work to change the future. The company was started with a skeleton crew of people and Clay. Now Seattle Genetics is looking to become a pharmaceutical heavy hitter with their headline drug, ADCetris a drug that can target cancer cells for destruction. Along with ADCetris, Seattle Genetics has about 20 marketable pharmaceutical items that bring in money for more research. Seattle Genetics currently has several contracts with GlaxoSmithKline, AbbVie, Genentech, and Pfizer.
Now days, Dr. Siegall works mainly in establishing funding for his research and development teams, but Clay has a very strong background in cancer research. Dr. Siegall received his Bachelor’s degree in Zoology and his PhD in Genetics from George Washington University. After earning his college degrees, Clay worked up through the ranks from the National Cancer Institute as a researcher to working in developing treatments at Bristol-Myers Squibb Pharmaceutical Research Institute.
Dr. Siegall also sets on several pharmaceutical and research centers Board of Directors; Fred Hutchinson Cancer Research Center, Mirna Therapeutics, and Alder Biopharmaceuticals. Dr. Siegall has 15 patents in his name and is an author of more than 70 publications. To read more about Dr. Siegall and Seattle Genetics please click here.